Breast Cancer Research and Treatment最新文献

{"title":"Efficacy of a novel interstitial lung disease monitoring program in breast cancer patients undergoing treatment with trastuzumab-deruxtecan.","authors":"Julie Williamson, Kristen Kelley, Mary Beth Scholand, Christine Crossno, Shelly Hummert, Patricia Jeppson, Holly Jacobson, Saundra Buys","doi":"10.1007/s10549-024-07586-2","DOIUrl":"https://doi.org/10.1007/s10549-024-07586-2","url":null,"abstract":"<p><strong>Purpose: </strong>Interstitial lung disease (ILD) is a well described and potentially fatal complication of trastuzumab-deruxtecan (T-DXd). It is currently unknown if specific monitoring is beneficial in the early detection of ILD in these patients. We describe the efficacy and feasibility of a novel ILD monitoring protocol in breast cancer patients treated with T-DXd at our institution.</p><p><strong>Methods: </strong>An ILD monitoring protocol developed at our institution included baseline and ongoing monitoring with pulmonary function testing (PFTs) and high-resolution chest computed tomography (HRCT) at pre-specified intervals. Patients with metastatic HER2+ or HER2-low breast cancer treated at Huntsman Cancer Institute who received ≥ 1 cycle of T-DXd between 2020 and 2023 were included (n = 68). Patient outcomes and provider adherence to the protocol were retrospectively evaluated. Providers were classified as \"no adherence\" if they did not elect to participate in any elements of the recommended protocol or as \"some adherence\" if they had at least some monitoring per protocol.</p><p><strong>Results: </strong>10 cases of ILD were identified with an incidence of 12% (3/25) in the no adherence group and 16% (7/43) in the some adherence group. ILD cases in the no adherence group included one grade 2 and two grade 5 cases. The some adherence group included three grade 1 and four grade 2 cases.</p><p><strong>Conclusion: </strong>An ILD monitoring protocol consisting of baseline PFTs and ongoing monitoring with PFTs and HRCT is a feasible approach as evidenced by a majority provider adherence rate. This type of protocol may be effective in preventing severe cases of ILD and identifying grade 1 events that may permit treatment re-challenge.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Classifying the molecular subtype of breast cancer using vision transformer and convolutional neural network features.","authors":"Chiharu Kai, Hideaki Tamori, Tsunehiro Ohtsuka, Miyako Nara, Akifumi Yoshida, Ikumi Sato, Hitoshi Futamura, Naoki Kodama, Satoshi Kasai","doi":"10.1007/s10549-025-07614-9","DOIUrl":"https://doi.org/10.1007/s10549-025-07614-9","url":null,"abstract":"<p><strong>Purpose: </strong>Identification of the molecular subtypes in breast cancer allows to optimize treatment strategies, but usually requires invasive needle biopsy. Recently, non-invasive imaging has emerged as promising means to classify them. Magnetic resonance imaging is often used for this purpose because it is three-dimensional and highly informative. Instead, only a few reports have documented the use of mammograms. Given that mammography is the first choice for breast cancer screening, using it to classify molecular subtypes would allow for early intervention on a much wider scale. Here, we aimed to evaluate the effectiveness of combining global and local mammographic features by using Vision Transformer (ViT) and Convolutional Neural Network (CNN) to classify molecular subtypes in breast cancer.</p><p><strong>Methods: </strong>The feature values for binary classification were calculated using the ViT and EfficientnetV2 feature extractors, followed by dimensional compression via principal component analysis. LightGBM was used to perform binary classification of each molecular subtype: triple-negative, HER2-enriched, luminal A, and luminal B.</p><p><strong>Results: </strong>The combination of ViT and CNN achieved higher accuracy than ViT or CNN alone. The sensitivity for triple-negative subtypes was very high (0.900, with F-value = 0.818); whereas F-value and sensitivity were 0.720 and 0.750 for HER2-enriched, 0.765 and 0.867 for luminal A, and 0.614 and 0.711 for luminal B subtypes, respectively.</p><p><strong>Conclusion: </strong>Features obtained from mammograms by combining ViT and CNN allow the classification of molecular subtypes with high accuracy. This approach could streamline early treatment workflows and triage, especially for poor prognosis subtypes such as triple-negative breast cancer.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999341","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessing the clinical utility of pre-operative neutrophil-lymphocyte ratio as a predictor of clinicopathological parameters in patients being treated for primary breast cancer.","authors":"Burce Isik, Matthew G Davey, Alisha A Jaffer, Juliette Buckley, Chwanrow Baban, Bridget Anne Merrigan, Shona Tormey","doi":"10.1007/s10549-025-07615-8","DOIUrl":"https://doi.org/10.1007/s10549-025-07615-8","url":null,"abstract":"<p><strong>Background: </strong>There is a paucity of data supporting the role of neutrophil-lymphocyte ratios (NLR) to determine clinicopathological parameters in patients being treated for primary breast cancer.</p><p><strong>Aims: </strong>To evaluate the association between pre-operative NLR and clinicopathological parameters in patients diagnosed with breast cancer.</p><p><strong>Methods: </strong>A retrospective cohort study was performed. This included consecutive patients indicated to undergo surgery for primary breast cancer at University Hospital Limerick between January 2010 and June 2017. NLR was expressed as a continuous variable. Univariable and multivariable linear regression analyses were used to determine the correlation between NLR and clinicopathological data. Data analytics was performed using SPSS v29.0.</p><p><strong>Results: </strong>673 patients met the inclusion criteria. Overall, the median preoperative NLR is 2.63 (standard deviation: 1.42). At univariable analysis, patient age (beta coefficient: 0.009, 95% confidence interval (CI) 0.001-0.017, P = 0.027), tumour size (beta coefficient: 0.013, 95% CI 0.005-0.021, P = 0.001), and human epidermal growth factor receptor-2 status (beta coefficient: - 0.370, 95% CI - 0.676-0.065, P = 0.017) were all predicted using NLR. However, at multivariable analysis, tumour size was the sole parameter predictable by NLR (beta coefficient: 0.011, 95% CI 0.002-0.019, P = 0.013).</p><p><strong>Conclusions: </strong>This study demonstrates that pre-operative NLR may serve as an independent predictor of tumour size in patients being treated with primary breast cancer. Ratification of these preliminary findings is warranted before robustly adopted into clinical practice.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinicopathologic characteristics of ductal carcinoma in situ and risk of subsequent invasive breast cancer: a multicenter, population-based cohort study.","authors":"Thomas E Rohan, Yihong Wang, Fergus Couch, Heather Spencer Feigelson, Robert T Greenlee, Stacey Honda, Azadeh Stark, Dhananjay Chitale, Chenxin Zhang, Xiaonan Xue, Mindy Ginsberg, Olivier Loudig","doi":"10.1007/s10549-024-07599-x","DOIUrl":"https://doi.org/10.1007/s10549-024-07599-x","url":null,"abstract":"<p><strong>Purpose: </strong>To study the association between clinicopathologic characteristics of ductal carcinoma in situ (DCIS) and risk of subsequent invasive breast cancer (IBC).</p><p><strong>Methods: </strong>We conducted a case-control study nested in a multicenter, population-based cohort of 8175 women aged ≥ 18 years with DCIS diagnosed between 1987 and 2016 and followed for a median duration of 83 months. Cases (n = 497) were women with a first diagnosis of DCIS who developed a subsequent IBC ≥ 6 months later; controls (2/case; n = 959) were matched to cases on age at and calendar year of DCIS diagnosis. Univariable and multivariable conditional logistic regression models were used to examine the associations between the DCIS characteristics of interest (non-screen detection of DCIS, tumor size, positive margins, grade of DCIS, necrosis, architectural pattern, microcalcification, and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status) and risk of IBC.</p><p><strong>Results: </strong>In the total study population, the associations were largely null. In subgroup analyses, there were strong position associations with punctate necrosis (pre/perimenopausal women), detection by physical exam (postmenopausal women), architectural patterns other than the main types (breast-conserving surgery [BCS]), and DCIS margins (ipsilateral cases), and inverse associations with HER2 positivity (BCS) and microcalcification (mastectomy); however, the associated confidence intervals were mostly very wide.</p><p><strong>Conclusion: </strong>The results of this study provide limited support for associations of the DCIS clinicopathologic characteristics studied here and risk of IBC.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"L-ICG as an optical agent to improve intraoperative margin detection in breast-conserving surgery: a prospective study.","authors":"Zi-Xuan Qiu, Li-Yun Xie, Ying-Zi Li, Ze-Chun Zhang, Hai-Lu Chen, Wan-Lin Zhan, Qin Huang, Jian-Hao Huang, Zhi-Yong Wu, Si-Qi Qiu","doi":"10.1007/s10549-025-07609-6","DOIUrl":"https://doi.org/10.1007/s10549-025-07609-6","url":null,"abstract":"<p><strong>Purpose: </strong>Precise tumor excision is important in breast-conserving surgery (BCS). This study explores the safety and accuracy of fluorescence image-guided BCS (FIGS) using a lidocaine mucilage-ICG compound (L-ICG).</p><p><strong>Methods: </strong>54 patients who underwent BCS from August 2020 to September 2023 were enrolled. L-ICG was locally injected 0.5 cm from the tumor border. FIGS was performed to guide the tumor excision. Frozen sectioning of surgical field biopsies was used to assess the intraoperative margin status. The primary outcome measures were margin width and positive margin rates. Cosmetic outcome was evaluated by the modified version of Breast-QTM Breast-Conserving Therapy Module (Postoperative) and breast cosmetic outcome assessment criteria.</p><p><strong>Results: </strong>The median cranial, caudal, medial, and lateral margin widths were 8 mm (interquartile range [IQR], 3-14), 5.5 mm (IQR, 2-15), 6 mm (IQR, 3-15), and 8 mm (IQR, 3-15), respectively. Five out of 54 (9.3%) patients had an intraoperative positive margin. Intraoperatively extended resection was performed for four patients and mastectomy for the remaining one. This further reduced the positive margin rate to 1.9% at final histopathology. 50 patients received cosmetic outcome evaluation, 100% of them were \"somewhat satisfied\" or \"very satisfied\" with the appearance of the operated breast when clothed and 98% of them were scaled as \"Good\" or \"Excellent\" in their appearance of the operated breast. No serious adverse events were observed. With a median follow-up of 12.8 months, no events for tumor relapse were observed.</p><p><strong>Conclusion: </strong>L-ICG-based FIGS is a promising technique to guide precise tumor excision in BCS.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A meta-analysis of the utility of cryotherapy for preventing peripheral neuropathy among breast cancer patients receiving paclitaxel and nab-paclitaxel.","authors":"Prashanth Ashok Kumar, Parth Sampat, Michael Sandhu, Vishnu Charan Suresh Kumar, Abigail Smith, Shweta Paulraj, Ghanshyam Ghelani, Danning Huang, Dongliang Wang, Abirami Sivapiragasam","doi":"10.1007/s10549-024-07597-z","DOIUrl":"https://doi.org/10.1007/s10549-024-07597-z","url":null,"abstract":"<p><strong>Background: </strong>Cryotherapy with taxane infusion is a noninvasive strategy for preventing peripheral neuropathy (PN), but the efficacy of this approach has not been proven.</p><p><strong>Methods: </strong>A systematic search was conducted, and 477 records were initially identified. The titles were screened independently by 2 reviewers. Fourteen studies were ultimately included for meta-analysis, which was conducted using the meta package in the R software. Only studies that analysed cryotherapy use in breast cancer patients who received paclitaxel or nab-paclitaxel were included. Relative risks (RRs) were calculated using the random effects model to compare the occurrence of PN between the paclitaxel and nab-paclitaxel groups.</p><p><strong>Results: </strong>The incidence of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 2 PN was 24.85% (81/326) in the cryotherapy arm and 42.35% (72/170) in the placebo arm. The overall RR CTCAE grade ≥ 2 PN in the cryotherapy group compared with the placebo group was 0.45 [0.27, 0.77, p = 0.0031]. The RR for sensory PN was 0.19 [0.05, 0.66, p = 0.009], and that for motor PN was 0.18 [0.03, 0.99, p = 0.0491]. The RR for Patient Neurotoxicity Questionnaire (PNQ) scores ≥ D, which indicate severe neuropathy, was 0.24 [0.09, 0.62; p = 0.0035]. Cold intolerance was the most reported t adverse effect, with a prevalence of 15% (37/247).</p><p><strong>Conclusions: </strong>The use of cryotherapy decreased the occurrence of CTCAE grade ≥ 2 PN by 55%. Cold intolerance was the most frequently reported adverse effect associated with cryotherapy, but this adverse effect did not lead to high discontinuation rates.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143000052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The role of statins in breast cancer survivors.","authors":"Saffiya Z Bashey, Avram Kordon, Kamari Ositelu, Anjali Rao, Nausheen Akhter","doi":"10.1007/s10549-024-07605-2","DOIUrl":"https://doi.org/10.1007/s10549-024-07605-2","url":null,"abstract":"<p><strong>Purpose: </strong>As breast cancer survival rates improve, cardiovascular disease (CVD) has become a critical concern among survivors due to co-morbidities and the cardiotoxic effects of cancer treatments. The risk of developing CVD in this population may surpass the risk of cancer recurrence. This review aims to analyze existing research on the use of statins in breast cancer survivors, focusing on their potential role in mitigating cardiovascular risk and cancer recurrence.</p><p><strong>Methods: </strong>The review begins by exploring the shared mechanisms underlying the development of both heart disease and breast cancer. It then examines the evidence for the role of statins in reducing cancer therapy-related cardiac dysfunction (CTRCD) and breast cancer recurrence, highlighting findings from the literature on their anti-inflammatory and lipid-lowering effects.</p><p><strong>Results: </strong>The analysis reveals that statins may offer benefits beyond their traditional cardiovascular applications. Evidence suggests that statins could reduce the risk of CTRCD and potentially lower the risk of breast cancer recurrence.</p><p><strong>Conclusions: </strong>Statins demonstrate promising potential in providing dual benefits for breast cancer survivors by mitigating CVD risk and possibly reducing the likelihood of cancer recurrence. However, additional studies are required to better understand the specific role of statins in breast cancer prevention and survivorship care.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142999831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sentinel lymph node biopsy in breast cancer: the role of ICG fluorescence after neoadjuvant chemotherapy.","authors":"Paweł Bogacz, Zuzanna Pelc, Radosław Mlak, Katarzyna Sędłak, Sebastian Kobiałka, Katarzyna Mielniczek, Magdalena Leśniewska, Katarzyna Chawrylak, Wojciech Polkowski, Karol Rawicz-Pruszyński, Andrzej Kurylcio","doi":"10.1007/s10549-025-07608-7","DOIUrl":"https://doi.org/10.1007/s10549-025-07608-7","url":null,"abstract":"<p><strong>Purpose: </strong>The purpose of this study was to evaluate the feasibility and safety of indocyanine green (ICG) fluorescence as an alternative to traditional sentinel lymph node biopsy (SLNB) techniques in breast cancer (BC) patients undergoing neoadjuvant chemotherapy (NAC). Specifically, the study aimed to assess sentinel node identification rates and the effectiveness of ICG in axillary staging without the use of radioactive tracers.</p><p><strong>Methods: </strong>This retrospective study included 71 BC patients treated with NAC, who underwent SLNB using ICG fluorescence between 2020 and 2024. ICG was injected intradermally around the nipple-areolar complex, and the lymphatic pathways were visualized with a fluorescence camera. SN identification rate (IR) and retrieval of three or more SNs were the primary and secondary endpoints, respectively. Statistical analyses were performed using the Mann-Whitney U test for continuous variables and Fisher's exact test for categorical variables.</p><p><strong>Results: </strong>ICG-guided SNs were identified in 91.5% of patients, with a median retrieval time of 25 min (range: 10-50). Three or more SNs were successfully collected among 66.2% of cases and 38% of patients achieved a complete pathological response to NAC, while 53.5% had partial responses. Metastatic SNs were found in 21.1% of patients, and no serious intraoperative or postoperative complications were observed.</p><p><strong>Conclusion: </strong>ICG fluorescence-guided SLNB proved to be a feasible and promising method for SNs identification among BC patients after NAC. While ICG shows potential as an alternative to traditional techniques, further studies are required to confirm these findings and to establish ICG role in post-NAC axillary staging.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142982806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study.","authors":"Jenny Nyqvist-Streng, Mikael Helou, Khalil Helou, Chaido Chamalidou, Anikó Kovács, Toshima Z Parris","doi":"10.1007/s10549-025-07610-z","DOIUrl":"https://doi.org/10.1007/s10549-025-07610-z","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the prognostic significance of changes in pre- and post-neoadjuvant chemotherapy (NACT) Ki67 in patients with primary invasive triple-negative breast cancer (TNBC).</p><p><strong>Methods: </strong>Population-based registry data were retrieved for patients diagnosed with TNBC between 2007 and 2021 (n = 9262). Multivariable Cox regression analysis was performed for disease-specific survival (DSS) and overall survival (OS) adjusted for age and residual disease in the breast and nodes (RDBN).</p><p><strong>Results: </strong>Of the 1777 TNBC patients receiving NACT, 54 achieved pathologic complete response (pCR) and 755 had residual disease. Most patients were overweight with stage II disease (78%), grade 3 tumors (53%), and RDBN score 3 (42%). Compared to baseline, tumor size (30 vs. 15 mm; P < 0.0001) and Ki67 levels (63% vs. 48%; P < 2.2e - 16) generally decreased after NACT. Although only 5% of samples increased in size, Ki67 levels often remained unchanged (75%) or increased (0.9%) after treatment, respectively. However, 34% of patients discontinued treatment. Patients showing no changes in Ki67% had more unfavorable OS (P < 0.0001) and DSS (P = 0.00032), with significantly lower 5-year survival probabilities (OS: 66%; DSS: 78%) than those with decreased Ki67% (OS: 87%; DSS: 89%). All patients reaching pCR were alive 5 years after diagnosis. However, only the RDBN score was an independent predictor of survival in the multivariable analyses.</p><p><strong>Conclusion: </strong>Ki67 often remained unchanged in TNBC patients treated with neoadjuvant chemotherapy, resulting in adverse clinical outcomes. These findings highlight the need for individualized treatment regimens and dynamic monitoring of TNBC patients with high Ki67 post-NACT.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142969666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA dynamics, PTEN/PI3K/AKT signaling, and their relationship to breast cancer: prospects for pharmaceuticals and natural product application.","authors":"Md Maniruzzaman, Md Rokibul Hasan Bhuiyan, Md Sadikuj Jaman, Md Shajedul Haque","doi":"10.1007/s10549-024-07600-7","DOIUrl":"https://doi.org/10.1007/s10549-024-07600-7","url":null,"abstract":"<p><strong>Background: </strong>Globally, Breast Cancer (BC) is the most frequent cancer in women and has a major negative impact on the physical and emotional well-being of its patients as well as one of the most common cancers to be diagnosed. Numerous studies have been published to identify various molecular pathways, including PI3K/AKT/PTEN. Moreover, growing evidence suggests that miRNAs have been found to play a vital role in the growth and carcinogenesis of tumors. Because of their crucial in the development and course of the illness, all other molecular variables, molecular pathways and microRNAs have gained recognition as important therapeutic targets in BC due to growing interest among researchers in utilizing synthetic drugs and natural products to target these signaling pathway with encouraging outcomes in vivo, in vitro and preclinical trials in recent years.</p><p><strong>Methods: </strong>We searched PUBMED, Science Direct, google scholar, Embase and Scopus for article published from the inception of each database to May 30, 2024.</p><p><strong>Results: </strong>We discussed PI3K/PTEN/AKT signaling pathway and microRNA activities with breast cancer cell line. In addition, this review covered a wide range of potential drug and natural products as targeted therapies that are linked to downregulating ER-α expression and activity, inhibiting proliferation, migration, metastasis and angiogenesis, inducing apoptosis, cell cycle arrest and sensitizing breast cancer cells. Many studies have been conducted, but as of right now, there are not enough articles to fully explain the treatment and research of breast cancer.</p><p><strong>Conclusions: </strong>We also need more and more studies on breast cancer from a variety of perspectives. Future scientist will find it easier to consider breast cancer treatment after reading this article presentation. So, the review focuses on our understanding of the roles that microRNA and PI3/PTEN/AKT signaling pathways play in regulating BC. Furthermore, we emphasized the potential therapeutic benefits of newly discovered inhibitors and the use of natural compounds in alone or combinations during preclinical trials.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142944676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}